Former FDA chiefs criticize DOGE as AstraZeneca AI partnership draws notice
Three former FDA commissioners condemned the Trump administration and former FDA officials over a major staff exodus. The newsletter also highlights an AI deal involving AstraZeneca and other pharmaceutical industry developments.
Three people who previously led the Food and Drug Administration have publicly criticized DOGE. Their condemnation targeted the Trump administration and onetime agency officials after a large wave of departures from the FDA. The same newsletter also highlighted a partnership involving AstraZeneca and artificial intelligence, along with other news from the drug sector.
The criticism from former FDA leaders and the reported staff departures could affect public confidence in the agency’s oversight role. Patients and healthcare providers may face uncertainty if regulatory processes are disrupted. The AstraZeneca artificial intelligence partnership may signal how drugmakers increasingly explore AI, potentially influencing research timelines, costs, and access, though its real effects remain unclear. Other pharmaceutical developments could shape industry priorities and, over time, treatment availability.